Moelis has started recruiting summer analysts directly into Healthcare/Life Sciences in addition to the generalist M&A / RX program in NY. Anyone know how strong the group is/culture at the firm?
| +267 | Why UBS Is the Worst Place to Start Your IB Career | 40 | 2d |
| +219 | UBS 2nd Year Analyst Q&A (2026) | 41 | 1d |
| +102 | What's your craziest "hardo" story? | 18 | 2h |
| +72 | UBS IB 26Q2 a Disaster! Advisory Revenue Down 23%, Capital MarketsDown 5% | 11 | 1h |
| +53 | Wolf of Wall Street vs. Reality: Anyone else feel scammed by the movies? | 19 | 16h |
| +50 | Suspended for a Year | 21 | 20h |
| +49 | Elite Boutique interview questions | 17 | 2d |
| +37 | so confused about 28 SA timeline | 30 | 11h |
| +34 | Lincoln International Return Offers | 8 | 29m |
| +33 | Rate my non-target resume | 19 | 5h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
I can provide a bit of color. Worked with the various NYC healthcare MDs while I was an analyst there. All solid guys. Friendly, knowledgeable, generally good WLB. I can see they may want people who know more about healthcare technicals as I was mainly knowledgeable about M&A finance stuff given I hadn’t taken a healthcare/sciences course since high school. I think when I was there, all the analysts kinda felt like 1 MD in 1 Hc vertical was kinda tough to work for and we all felt like we had to take one for the team and everyone had to take a turn working on one of that MDs deals. I closed a nice deal with him and thought it was manageable but I can understand why others may not have actively sought to work for him. The good news is that it seems like the MD himself recognized that might not have been the best role for him and now is like the CSO at a major client. Looks like he has a great job and I’m happy for him. Overall, the rest of the team/MDs that I believe are still there are all solid, nice guys to work for in my opinion. Not sure if I have much more color to give you at this time as my info is a few years or so old
Def can say that overall the deal flow is good; though a fair amount of it at the time was with the harder MD but I think Moelis still does well without him. I think Ken has been saying for a while now how excited he is about the HC space and how big the opportunity is for Moelis in that realm and how much he wants to invest in servicing the sector.
How were the exits? VC, any PE?
Curious how it stacks up against the generalist program
Deleted
Noooooooooooo
As an update. The Moelis NY HC team has basically disbanded and are rapidly trying to hire new MDs and Mid-level management. Group head became the cfo of a Midwest Fortune 500 company. Guy made up about 40% of dealflow for the group and a lot of his supporting guys left for other groups.
Is this HC services or bio pharma?
Biopharma (life sciences)
do you mind sharing who?
did this happen again? the old life sci group head left a couple years ago to become a cfo but moelis represented them when his company got bought earlier this year
Didn't one of their senior bankers leave for PJS?
That’s one guy but op said the entire group is getting disbanded so are the other hc mds leaving too?
Was a period of time 2 months ago when the life sci group didn’t have a single VP and 1-2 associates. Just so happened to coincide with analyst buyside recruitment and due to Covid many positions were immediate starts. So over the course of a month or so, give or take more than half the group was gone.
How many MDs are left in the group though for lifesci
Not sure, my source is a close friend who was one of the folks who recently departed. But given the brand name and pay structure, I’m sure they can rehire. But will certainly have some growing pains in the next year or so.
Bump
bump
Exercitationem qui vitae perferendis quia voluptas sed iusto. Ducimus ab alias qui. Molestiae delectus perferendis omnis eligendi cum et eius.
Alias harum dolorem natus nam magnam. Odit enim aliquid rerum nihil. Nostrum rerum in dignissimos aut sit nulla voluptate. Distinctio aut ducimus eveniet earum sunt beatae dolor. Cumque id ut eveniet tenetur est sapiente. Consectetur consequatur necessitatibus eligendi ut.
Soluta non dolor est quaerat commodi. Distinctio aspernatur impedit mollitia et praesentium illo mollitia exercitationem. Consequuntur aut perspiciatis incidunt reprehenderit nesciunt. Enim consequatur corporis ab totam facilis nostrum. Commodi fuga omnis ex et consequatur. Omnis sint voluptatibus iusto accusantium. Aperiam ex ipsa omnis sit.
Odit sit cum est expedita recusandae. A omnis dolores at reiciendis vel aut ut. Aut eum enim dignissimos expedita quo tempora ipsum. Non eum dolores blanditiis qui.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...